uniQure (NASDAQ:QURE) Price Target Raised to $56.00 at The Goldman Sachs Group

Key Points

• The Goldman Sachs Group raised uniQure's price target significantly from $13.00 to $56.00, predicting a potential upside of 10.53% from its previous close.
• Other analysts have also increased their targets, with Guggenheim setting a target of $95.00 and a "buy" rating, as part of a generally positive sentiment towards the stock.
• uniQure's stock rose 6.7% during midday trading, reaching $50.66, with a historical trading volume substantially above its average.

uniQure (NASDAQ:QURE - Get Free Report) had its price target increased by The Goldman Sachs Group from $13.00 to $56.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a "neutral" rating on the biotechnology company's stock. The Goldman Sachs Group's target price would suggest a potential upside of 10.53% from the stock's previous close.

Other analysts have also issued reports about the company. Guggenheim raised their target price on uniQure from $28.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Wednesday. Chardan Capital raised their price objective on uniQure from $35.00 to $76.00 and gave the company a "buy" rating in a report on Thursday. Stifel Nicolaus raised their price objective on uniQure from $30.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Leerink Partners raised their price objective on uniQure from $48.00 to $68.00 and gave the company an "outperform" rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $64.64.

uniQure Stock Up 6.7%

uniQure stock traded up $3.16 during midday trading on Thursday, reaching $50.66. The company's stock had a trading volume of 11,956,075 shares, compared to its average volume of 1,792,562. The stock's 50-day simple moving average is $15.90 and its 200-day simple moving average is $14.32. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. uniQure has a 52-week low of $4.45 and a 52-week high of $54.98. The stock has a market capitalization of $2.78 billion, a P/E ratio of -12.72 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. The business had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, sell-side analysts expect that uniQure will post -3.75 EPS for the current year.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the stock. Main Management ETF Advisors LLC lifted its position in uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company's stock worth $786,000 after buying an additional 912 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock worth $99,000 after buying an additional 5,538 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in uniQure in the second quarter valued at $117,000. Birchview Capital LP raised its position in uniQure by 11.3% in the second quarter. Birchview Capital LP now owns 98,697 shares of the biotechnology company's stock valued at $1,376,000 after purchasing an additional 10,000 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in uniQure by 3.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 279,999 shares of the biotechnology company's stock valued at $2,968,000 after purchasing an additional 10,019 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.